Evaluating Differences in the Disease Experiences of Minority Adults With Cystic Fibrosis

Kia Hutchins, BS1, Eileen Barr, MS CGC1, Cecelia Bellcross, PhD, MS CGC1, Nadia Ali, PhD, ScM1, and William R. Hunt, MD2

Abstract

Extensive research has demonstrated disparities in health outcomes and survival between non-Hispanic Caucasian (NHC) and non-Caucasian or Hispanic (minority) persons with cystic fibrosis (CF) in the United States (US). However, very little research has been done to explore the disease experiences of racial and ethnic minority persons with CF. Adult subjects with CF were approached for study participation and to characterize their experiential disease perceptions. Survey data were analyzed using Chi-Square tests and Mann-Whitney U-test for basic categorical and continuous variables, and Kruskal-Wallis one-way ANOVA using ranks for Likert scales. Minority persons reported significantly lower scores (more negative experience) when comparing themselves to others with CF (15.18 ± 2.89 vs 18.40 ± 3.18, P < .01), particularly in the areas of representation in research, experience, and support. We were able to identify the unique experiences of minority persons with CF, including perceived lower disease understanding and poorer representation compared to most others with CF. Further large studies are needed to develop and assess interventions that may be useful for serving these diverse populations.

Keywords

Culture/diversity, outpatient satisfaction data, patient feedback, patient perspectives/narratives, relationships in healthcare

Background

Cystic fibrosis (CF) is a genetic condition caused by mutations in the CF transmembrane conductance regulator (CFTR) gene (1). Dysfunction of this gene results in a buildup of mucus in the airways, pancreatic insufficiency, and other co-morbidities (1). CFTR carrier rates are highest amongst non-Hispanic Caucasians (NHC). However, CF is by no means racially unique (1). CF affects approximately 1 in 3000 individuals of Caucasian descent, 1 in 8000 individuals of Hispanic descent, 1 in 15 000 individuals of African American descent, and 1 in 30 000 individuals of Asian American descent (1). Within the United States in 2020, there were 31 411 individuals with CF accounted for in the national CF registry. Of these, 93.4% identified as White, 4.7% identified as African American, 3.9% identified as “Other Race,” and 9.6% identified as Hispanic (2). As new research has developed more effective treatments, the median survival of persons with CF has steadily improved to 50.0 years by 2020 (2). While CF survival has increased overall, equal improvements have not been observed within non-Caucasian or Hispanic (racial and ethnic minority) populations, and exciting new therapies such as CFTR modulators appear to disproportionately benefit NHC persons with CF due to their more common mutations (3–6). Private or rare mutations, which are more commonly seen in racial and ethnic minority persons with CF, often do not have approved modulators.

Previous research has explored differences between Hispanic and non-Hispanic persons and found that disparities in survival and lung function between these groups exist even after accounting for typical morbidities (6,7). In a 2018 retrospective cohort analysis of over 26 000 persons with CF, Rho et al (6) found that Hispanic persons had lower survival overall, with a mean age at death of 22.4 ± 9.9 years.

1 Department of Human Genetics, Emory University, Atlanta, GA, USA
2 Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, USA

Corresponding Author:
William R. Hunt, Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, 1605 Chantilly Drive, 3rd Floor CF Offices, Atlanta, GA 30327, USA.
Email: randy.hunt@emory.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
compared to a mean age at death of 28.1 ± 10.0 years for non-Hispanic persons. McGarry et al (7) found that across the United States, Hispanic persons with CF had lower lung function, with a forced expiratory volume in one second (FEV₁) 4.0% to 9.0% lower than non-Hispanic persons with CF, depending on the region in the United States. Outside of objective disease outcomes, non-Caucasian persons with CF had a poorer quality of life after accounting for socioeconomic status and other co-morbidities (8). Despite research demonstrating differences in quantifiable health outcomes and health-related quality of life, very little research has been done to explore the disease experiences of racial and ethnic minority persons with CF. Multiple studies have demonstrated patients’ adherence to chronic disease management is directly correlated to their perceptions of disease and cultural experience (9,10). For example, studies such as Adzika et al (11) show the strong influence that supportive familial and social environment plays on the health-related quality of life of sickle cell anemia patients. Further research is needed in this area to explore if there are differences in cultural and disease perceptions between Caucasian and non-Caucasian persons with CF, and if there are, to ultimately optimize disease experience and health outcomes for all peoples.

The goal of this study was to comparatively explore disease-specific experiences and cultural contributions for racial and ethnic minority persons with CF. Identifying factors that contribute to a more negative disease experience among racial and ethnic minority persons will establish a basis for further research that could quantify the differences and promote better healthcare practices for physicians and other allied health clinicians. To our knowledge, this is the first study to comparatively explore the more subjective disease experiences of NHC and racial and ethnic minority persons with CF.

**Methods**

**Participants and Data Collection**

Subjects met inclusion criteria if they were 18 years of age or older, previously diagnosed with CF, and were a patient at the local academic adult CF care center. Participants were excluded if they were incarcerated or if they could not read English. The study protocol was reviewed and approved by the local institutional review board (IRB00117205). Participants were recruited via email from the clinic mailing list in an open-recruitment style. Following informed consent, subjects completed an online survey to assess self-perception of disease, experiences with healthcare, family, culture, and community support, and self-comparison to others with CF (Supplemental Document 1). The survey was distributed 3 times between January 2020 and December 2020, and took 5 to 10 min to complete. If participants self-identified as White and Non-Hispanic they were included in the NHC cohort. Participants were included in the racial and ethnic minority cohort (minority) if they identified as either Hispanic and/or American Indian or Alaska Native, Asian, Black, or African American, Native Hawaiian, or Pacific Islander, “Mixed” or “other” race.

**Measures**

Several questions in the survey were selectively drawn from the Illness Perceptions Questionnaire-Revised (IPQ-R), a survey validated for several chronic diseases, including CF (12). These Likert-type questions were scored consistently with the IPQ-R methodology. Survey questions also included multiple-choice Likert-type questions and open-answer questions. Likert-type items were scored 1 to 5, with 1 being “strongly disagree” and 5 being “strongly agree.” Within the survey, 8 questions were reverse scored. Higher scores indicate more positive experiences, while lower scores indicate more negative experiences. A score of 3.5 or higher was considered a “positive” response and reflects the subject general agreement with the Likert-question statement. Open-ended questions were included in each section to allow participants to expand upon their experience of CF illness including diagnosis, perception of family/culture/community influences, quality of CF care, and comparisons of their disease experience compared to others with CF.

**Statistical Analyses**

Survey data were analyzed using several statistical tests. Data was evaluated for normality using kurtosis and skewness. Shapiro-Wilk analysis was utilized to assess the normality of continuous data. For nonparametric data, categorical and continuous variables were compared using Chi-square and Mann-Whitney U-test, respectively. The median age of diagnosis was further compared by independent samples median analysis. Kruskal-Wallis one-way ANOVA using ranks for Likert scales was performed to compare experiences between the groups. Each individual Likert-type question was compared between the minority and NHC populations, as were the Likert scales for the 4 primary evaluation areas: self-perception of disease, experiences with healthcare, families, cultures, communities, and self-comparison to others with CF. Correction for multiple pairwise comparisons was performed. In order to compare the frequency of emotions reported by participants, Fisher’s exact test was utilized as more than 20% of the cell counts were less than 5. Subsequent post-hoc analysis was performed between groups further divided based on gender (ie, minority male, minority female, NHC male, NHC female). Between group and gender comparisons of Likert-scale data were analyzed by Kruskal-Wallis one-way ANOVA with subsequent Bonferroni correction for multiple-comparison correction. A \( P \leq .05 \) was set to determine significance. Open answer questions from this survey are considered pilot data and therefore did not receive complete thematic analysis. All statistical analyses were conducted using IBM SPSS version 27.
Results

Participant Demographics

Of 330 possible subjects, 82 completed the survey (24.8% response rate). The characteristics of survey respondents are shown in Table 1. Of participants, 85.4% were NHC, which is consistent with the demographics of the clinic from which the participants were recruited. Of respondents, 63.4% were assigned female at birth, with one respondent identifying as nonbinary or transgender. The median age at diagnosis was 1.0 years for NHC and 2.5 years for minorities. There was no significant difference in income or age at diagnosis between NHC and minority subjects. There was a significant difference in education level, with NHC participants reporting higher rates of some tertiary education or higher. Additionally, there were differences in self-reported parental income, with NHC reporting a higher percentage of parents earning an annual income of $50,000 or more (P < .01). Supplemental Table 1 displays the specific racial and ethnic characteristics of the minority respondents. Hispanic or Latinx participants made up 16.7% of the minority sample. Black or African American and Asian participants made up 66.7% and 8.3%, respectively. No participants self-identified as Native American or Alaska Natives, and 2 participants reported being “other” or mixed race.

Perception of Illness

Minority participants rated themselves significantly lower in their understanding of CF than NHC participants (3.67 ± 0.99 vs 4.37 ± 0.85, P < .01). Minority participants also had lower overall scores on the entire perception of illness scale (29.58 ± 4.81 vs 32.97 ± 4.47, P < .05) (Table 2).

Emotions Associated With Disease

On average, a higher percentage of minority subjects reported more negative (4.08 vs 2.81, P < .05) and approximately the same amount of positive (0.67 vs 0.74, P = .668) emotions

Table 1. Participant Demographics (N = 82).

|                          | Total (n) | Non-Hispanic Caucasian (NHC) | Minority | P-value |
|--------------------------|-----------|------------------------------|----------|---------|
| Total (n)                | 70        | 12                           |          |         |
| Age at diagnosis (years) |           |                              |          |         |
| Mean (± standard deviation) | 10.17 ± 18.76 | 4.56 ± 6.33 | .645     |         |
| Median                   | 1.00      | 2.50                         | .447     |         |
| Range                    | 0-63      | 0-22                         |          |         |
| Sex n (%)                |           |                              |          | .873    |
| Female                   | 44 (62.9%)| 8 (66.7%)                    |          |         |
| Education n (%)          |           |                              |          | .038    |
| Secondary education or less | 11 (15.7%) | 7 (58.3%)                    |          |         |
| Undergraduate education  | 38 (54.3%)| 3 (25%)                      |          |         |
| Graduate education       | 21 (30%)  | 2 (16.7%)                    | .109     |         |
| Annual income n (%)      |           |                              |          |         |
| Less than $50,000        | 34 (50.0%)| 9 (75.0%)                    |          |         |
| $50,000 or more           | 34 (50.0%)| 3 (25.0%)                    |          |         |
| Parental education n (%) |           |                              |          |         |
| Mother<sup>a</sup>       |           |                              |          | .391    |
| Secondary education or less | 17 (25.8%) | 5 (45.5%)                    |          |         |
| Undergraduate education  | 38 (57.6%)| 5 (45.5%)                    |          |         |
| Graduate education       | 11 (16.7%)| 1 (9.1%)                     | .494     |         |
| Father<sup>b</sup>       |           |                              |          |         |
| Secondary education or less | 15 (22.7%) | 4 (40%)                      |          |         |
| Undergraduate education  | 32 (48.5%)| 4 (40%)                      |          |         |
| Graduate education       | 19 (28.8%)| 2 (20%)                      |          |         |
| Parental annual income n (%)<sup>c</sup> | | | | | |
| Less than $50,000        | 10 (17.5%)| 5 (62.5%)                    | .005     |         |
| $50,000 or more           | 47 (82.5%)| 3 (37.5%)                    |          |         |

<sup>a</sup>NHC n = 66, minority n = 11.
<sup>b</sup>NHC n = 66, minority n = 10.
<sup>c</sup>NHC n = 57, minority n = 8.

Table 2. Perception of Illness.

| Statement                                         | Non-Hispanic Caucasian (NHC) (n = 70) | Minority (n = 12) | P-value |
|---------------------------------------------------|---------------------------------------|-------------------|---------|
| *My illness strongly affects the way others see me| 3.36 ± 1.13                            | 2.67 ± 1.16       | .055    |
| *My illness has serious financial consequences    | 2.23 ± 1.18                            | 1.75 ± 0.97       | .166    |
| *My illness causes difficulties for those close to me| 2.71 ± 1.12                            | 2.17 ± 1.12       | .095    |
| What I do can determine whether my illness gets better or worse | 4.17 ± 0.85 | 3.83 ± 1.03 | .270  |
| The course of my illness depends on me             | 3.81 ± 0.97                            | 3.58 ± 1.24       | .546    |
| The negative effects of my illness can be prevented (avoided) by my treatment | 3.51 ± 0.93 | 3.50 ± 0.67 | .818  |
| *Nothing I do will affect my illness              | 4.37 ± 0.80                            | 4.17 ± 0.72       | .246    |
| *My actions will have no effect on the outcome of my illness | 4.43 ± 0.67 | 4.25 ± 0.75 | .408  |
| I have a clear picture or understanding of my condition | 4.37 ± 0.85 | 3.67 ± 0.99 | .009  |
| Perception of illness total score                  | 32.97 ± 4.47                           | 29.58 ± 4.81      | .021    |

Scores are reported as a mean ± standard deviation, and P-value was calculated using Kruskal-Wallis one-way ANOVA with ranks. Higher scores indicate a more positive experience range = 1–5. Asterisks (*) indicate questions that were reverse scored. Statements were selectively drawn from the IPQ-R.
when thinking about their CF than did NHC subjects (Table 3). Specifically, minority subjects were significantly more likely to endorse experiencing both depression and anxiety compared to the NHC group (83.3\% vs 31.4\%, \( P < .001 \), 83.3\% vs 48.6\%, \( P < .05 \), respectively). The most commonly reported emotions among NHC participants were worry/concern, anxiety, gratitude, and depression. Minority participants commonly expressed these as well, in addition to fear and anger.

**Quality-of-Care**

There were no significant differences reported on quality-of-care measures between NHC and minority participants (Supplemental Table 2). Overall, both minority and NHC participants expressed satisfaction with their current CF care. Statistically, there were no differences between groups in their perceived appropriateness for their timing of diagnosis, with similar percentages endorsing that their diagnosis was made either earlier or later than expected (\( P = .391 \), \( n = 70 \)). However, in open-ended questioning, several minority participants believed they were diagnosed later due to healthcare providers not suspecting CF because of their ethnicity. One participant of self-reported Asian ancestry shared: “They didn’t think to test me for CF because of my ethnicity. One doctor had to convince the others to test me and they thought she was crazy for it.”

**Family, Culture, and Community Support**

There were no statistically significant differences identified between minority and NHC persons in familial/community support (Supplemental Table 3). In the survey comments, many subjects recounted a lack of public familiarity with CF, support from family members, and familial education levels and how they contributed to support.

**Comparison to Others With CF**

Minority persons reported significantly lower scores on the Likert scale when comparing themselves to others with CF (15.18 \( \pm \) 2.89 vs 18.40 \( \pm \) 3.18, \( P < .01 \)), with lower scores indicating their experience was perceived as worse than most others with CF (Table 4). This was significantly different in the areas of representation in research (1.91 \( \pm \) 1.38 vs 3.09 \( \pm \) 1.27, \( P < .01 \)) and support from family and community (3.18 \( \pm \) 1.08 vs 4.03 \( \pm \) 1.12, \( P < .05 \)). One participant shared: “I hate to say this but I am black and not [too] many of us have CF so I don’t get any influence.” Both minority and NHC participants shared that while they felt that they may not be represented as well in research due to their race, ethnicity, or milder clinical presentation, most did not express distress over this. Rather, they expressed hope for future research or that existing research will equally benefit them.

**Gender Differences Between Groups**

Further comparisons between groups separated by gender demonstrated significant differences. Within the category of “perceptions of illness,” minority females were much less likely to agree with the statement “I have a clear picture or understanding of my condition” than their NHC female peers (Figure 1A). This difference amongst females was the primary driver of the difference between the racial groups in
this category. Female minority subjects were also significantly less likely to agree that they were well represented in CF research compared to their NHC counterparts (Figure 1B). There were trends toward female minority subjects reporting worse experiences in general when compared to both male and female NHC subjects, but these did not meet statistical significance when corrected for multiple comparisons.

Discussion

This study is the first to document the subjective and perceived disease experiences of NHC and racial and ethnic minority persons with CF in the areas of disease perception, quality of care, cultural and community support, and comparison of others with CF. The most notable differences between racial groups were found in the perception of illness, endorsement of negative emotions associated with their disease, and comparison to others with CF, particularly in regards to representation in CF research.

Minority persons with CF reported feeling they had a significantly lower understanding of their disease and more negative perceptions of their illness overall when compared to NHC participants. This was most prevalent in females between racial groups. Previous data has demonstrated limited understanding of disease manifestations is a significant source of mental distress for both patients and their

Figure 1. Gender difference between groups. (A) Degree of agreement with the statement “I have a clear picture or understanding of my condition” within the category of perception of illness. There were significant differences between minority female subjects and NHC subjects (3.5 ± 1.07 vs 4.47 ± 0.81, P < .05). (B) Degree of agreement with the statement, “Representation of people like me in CF research and campaigns is” with the comparison to others with the CF category (1.57 ± 0.98 vs 3.32 ± 1.22, P < .01). (C) Total scores of agreement in the comparison to others with the CF category. There were trends toward differences between female minority subjects compared to female NHC subjects, but these did not meet statistical significance following Bonferroni correction for multiple analyses (15.0 ± 3.06 vs 18.57 ± 3.32, P = .067).

Abbreviations: NHC, Non-Hispanic Caucasian; CF, cystic fibrosis.
caregivers (13). These perceptions may be related to several complex factors. One possibility is that this difference may be related to a limited understanding of CF by family and community members, as the cultural or community support of persons with CF may play a large role in their management of care and experience of their illness (14,15). While no significant differences were noted in the cultural and community support portion of the survey, in the comparison to others section, minority participants perceived their support from family and community as significantly lower than NHC participants. Several participants expanded upon this in the survey comments section. One topic broached across both minority and NHC participants was unfamiliarity with CF within their communities. This experience may be particularly exacerbated within minority communities due to the lower prevalence of CF (2). As one participant wrote: “I am Black with what is known as white people’s disease. So, not many people knew or cared what was going on with me. I got a lot of ‘eww, why does she keep coughing’, as if I had something that they could catch.” Several minority participants expressed that while they received support, they felt that their families and communities had insufficient understanding of their condition: “African Americans are rarely affected by CF. Therefore, my circle of family and friends are not very knowledgeable of the illness, and white Americans in my circle tend not to believe that I have the illness.”

Another possible explanation for the perceived lower understanding may be the limited representation of minority individuals in CF research and campaigns. Minority participants, particularly females, were significantly less likely to agree that representation of people similar to them was the same or better in CF research and/or campaigns. These results are unsurprising, as the underrepresentation of minorities in CF drug trials has been documented previously (16). This may lead to some disconnect from the community and distance from ongoing CF research, causing feelings of decreased understanding about the disease and new treatments. The CF foundation has begun prioritizing research for communities of color to begin to rectify the disparities outlined above (5,17). What is perhaps more surprising is that while minority participants reported poorer representation, further elaboration revealed a sense of survivor’s guilt and gratitude for how existing research does benefit them: “I ... often feel as though I am far healthier than others with CF. I have survivor’s guilt sometimes, especially when I think about those I’ve lost ... makes me feel an odd sense of guilt for being so healthy.” Acknowledgment of disparities and empathy for those who research does not currently benefit, however, is not a substitute for research that better represents all individuals affected with CF. These contradictory findings suggest that future research is needed to clarify the nuances of this complex experience.

It is important to note that these differences in understanding of CF are perceived differences. As objective knowledge was not assessed, there may or may not be a true difference in disease knowledge/understanding between these groups. However, we believe it is important to explore the implications of a perceived lack of knowledge and the possible impact it may have on disease experience.

Both NHC and minority subjects reported frequent negative emotions associated with their CF illness including depression, fear, and worry. However, minority participants were significantly more likely to express anxiety and depression in regards to their illness and were more likely in general to endorse negative emotions than their NHC counterparts. It is possible these emotions are associated with worse physical health outcomes as multiple studies have demonstrated worse clinical outcomes in minority persons with CF, even after adjusting for socioeconomic status (3,6,18). However, specific cultural experiences may also be exacerbating this difference. Unsurprisingly, experiential racism has been significantly associated with mental health outcomes in a large meta-analysis (19). Along these lines, some minority participants acknowledged that their personal life experiences deeply influenced their experience with CF: “I am from a family that has suffered a lot in this country, cycles of poverty, violence and abuse are all parts of my lineage ... Food shelters, homelessness, and turmoil formed my childhood ... My life is different now, I am a high earner and live in a very stable environment but, it took me getting here to really see how bad it was.” Intergenerational and personal trauma are more prevalent in minority individuals, and can influence mental health concerns to which individuals with chronic illnesses like CF may already be prone (20,21). Both minority and NHC participants expressed a sense of lack of control they feel over their CF: “I feel like no matter what I do far as taking my meds I have no control with the outcome of my condition. I feel like I do everything right and sometimes the doctor still tell me bad news ... Hard to deal with at times, when you do your treatments and still feel like it isn’t enough.” There is growing recognition of the importance of resilience in chronic disease management (22). These data would suggest that a better understanding of the emotions and disease experience of persons with CF are important when conceptualizing approaches to bolster resiliency and improving the entirety of their disease management.

While no differences were apparent in the quality-of-care quantitatively, some nuanced topics emerged in the survey comments. The first being delayed diagnosis due to clinician biases: “the rarity of African Americans having CF made the diagnosis come later. No one suspected me to have it [because] of my ethnicity.” Because all participants are over the age of 18, it is unlikely that they went through a newborn screening (NBS) program for CF. While a few states performed NBS for CF before 1997, NBS for CF was not adopted in all 50 states until 2007, after all, participants were born (23,24). While NBS has improved the identification of affected individuals and reduced diagnostic bias from healthcare providers, studies have shown that due to the limited nature of CF NBS in many states, and the wider genotypic heterogeneity among minority persons with CF, screening disproportionately fails to pick up CFTR mutations in minorities (25,26). One way to decrease the diagnostic disparity among these groups may be to move towards
sequencing CFTR rather than common variant panels (27). This is in addition to broad educational initiatives to the general population to dispel the myth that CF is racially unique.

By exploring the potential cultural and disease experiential differences between Caucasian and non-Caucasian persons with CF, some insight can be gleaned for interventions or development of support structures focused on attenuating negative psychosocial experiences. This may help improve clinical outcomes of minority persons with CF. For example, this study demonstrated there is a significantly higher endorsement of anxiety and depression associated with disease experience in minority persons with CF. Given this, regular mental health screening with simple clinical screens such as the Generalized Anxiety Disorder – 7 and the Personal Health Questionnaire – 9 should be performed on all persons with CF (28). Special attention to offering resiliency training to cultivate mindfulness and self-care would be important for any person with CF, but particularly minorities. This study also found that minority persons with CF were significantly less likely to feel represented in research. It is critically important that research be inclusive and representative of the whole CF population (5,16). To this aim, it is important to recruit diverse patient partners to participate on research development committees and make special efforts to attenuate any social or economic barriers that may inadvertently discriminate and preclude minority persons with CF from participating in research. Finally, while there were no quantitative differences in perceived quality of healthcare between groups in this study, open-ended survey question responses suggested minority persons experience healthcare struggles both before and after their CF diagnosis. Previous studies have demonstrated implicit biases do exist in healthcare professionals at low to moderate levels (29). Instituting implicit bias training as well as cultural competency training is an important measure to take among healthcare professionals to lessen the effect of bias and hopefully reduce harm.

This study has several limitations. One shortcoming is the small sample size, which in part resulted from difficulties with recruitment due to COVID-19. Minority persons are a small, but important portion of the CF population, and sampling from a single CF center limited the number of potential participants. Additionally, it is possible that the patients at the CF care center we recruited from may not be representative of the larger CF population. The inability to separate out individuals of different minorities is also a limitation, as there are unique differences that can be lost when grouped together. The COVID-19 pandemic and a limited survey collection period may have created barriers for individuals with limited access to technology or the internet when clinic visits were moved virtually. Future studies should implement a similar approach on a larger scale, collecting participants from across the country and internationally.

We believe that this study is an important addition to the limited existing literature regarding the subjective experiences of minority persons with CF. It is effective in highlighting the experiences of minority persons with CF, including their self-reported perception of less understanding when compared to NHC, a more negative experience compared to others with CF, and complex emotions surrounding those disparate experiences with a higher endorsement of anxiety and depression. This study has revealed the need to foster education surrounding CF in minority communities, open and continuous communication and education between patients and providers, and the importance of increasing representation of minorities in CF research. Further research studies will be needed to evaluate these questions on a larger scale and to develop and assess interventions that may be useful for serving these populations. In particular, qualitative comments from participants suggest there is more to the story than was captured by quantitative data alone. The future qualitative investigation would be helpful to enrich our understanding of the present data.

**Author Contributions**

Kia Hutchins—Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Writing, original draft, review & editing. Eileen Barr—Conceptualization, Methodology, Formal analysis, Writing – review & editing. Cecelia Bellcross—Conceptualization, Project administration, Resources, Supervision, Writing–original draft, Writing–review & editing. Nadia Ali—Formal analysis, Methodology, Project administration, Resources, Supervision, Validation, Writing–review & editing. William R. Hunt—Conceptualization, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Visualization; Writing–review & editing.

**Declaration of Conflicting Interests**

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Ethics Approval**

This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was reviewed and approved by the Emory University institutional review board (IRB00117205). Informed consent was obtained from all individual participants in the study.

**Funding**

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Georgia Association of Genetic Counselors Student Grant (Ms Kia Hutchins).

**ORCID iD**

William R. Hunt [](https://orcid.org/0000-0002-1882-7132)

**Statement of Human and Animal Rights**

All procedures in this study were conducted in accordance with the Emory University institutional review board (IRB00117205) approved protocols.

**Statement of Informed Consent**

Written informed consent was obtained from the patients for their anonymized information to be published in this article.
Supplemental Material
Supplemental material for this article is available online.

References
1. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891–904.
2. Foundation CF. 2020 Annual Data Report. Cystic Fibrosis Foundation Patient Registry. 2021 (1).
3. Buu MC, Sanders LM, Mayo JA, Milla CE, Wise PH. Assessing differences in mortality rates and risk factors between Hispanic and non-Hispanic patients with cystic fibrosis in California. Chest. 2016;149(2):289–90.
4. Kerem E, Cohen-Cymerknoh M. Disparities in cystic fibrosis care and outcome: socioeconomic status and beyond. Chest. 2016;149(2):298–300.
5. McGarry ME, McCollery SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol. 2021;56(6):1496–503.
6. Rho J, Ahn C, Gao A, Sawicki GS, Keller A, Jain R. Disparities in mortality of Hispanic patients with cystic fibrosis in the United States. A national and regional cohort study. Am J Respir Crit Care Med. 2018;198(8):1055–63.
7. McGarry ME, Neuhaus JM, Nielson DW, Ly NP. Regional variations in longitudinal pulmonary function: a comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States. Pediatr Pulmonol. 2019;54(9):1382–90.
8. Quittner AL, Schechter MS, Rasouliyan L, Haselkorn T, Pasta DJ, Wagener JS. Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States. Chest. 2010;137(3):642–50.
9. McAndrew LM, Musumeci-Szabo TJ, Mora PA, Vileikyte L, Burns E, Halm EA, et al. Using the common sense model to design interventions for the prevention and management of chronic illness threats: from description to process. Br J Health Psychol. 2008;13(2):195–204.
10. Russell BE, Gurrola E, Ndumele CD, Landon BE, O’Malley JA, Keegan T, et al. Perspectives of non-Hispanic black and Latino patients in Boston’s urban community health centers on their experiences with diabetes and hypertension. J Gen Intern Med. 2010;25(6):504–9.
11. Adzika VA, Gloczh FN, Ayim-Aboaigye D, Ahoeru CS. Socio-demographic characteristics and psychosocial consequences of sickle cell disease: the case of patients in a public hospital in Ghana. J Health Popul Nutr. 2017;36(1):4.
12. Hill S. The illness perceptions questionnaire-revised (IPQ-R). J Physiother. 2010;56(4):280.
13. Gysels M, Bausewein C, Higginson IJ. Experiences of breathlessness: a systematic review of the qualitative literature. Palliat Support Care. 2007;5(3):281–302.
14. Cockerham WC, Hamby BW, Oates GR. The social determinants of chronic disease. Am J Prev Med. 2017;52(1S1):SS–S12.
15. Flewelling KD, Sellers DE, Sawicki GS, Robinson WM, Dill EJ. Social support is associated with fewer reported symptoms and decreased treatment burden in adults with cystic fibrosis. J Cyst Fibros. 2019;18(4):572–6.
16. McGarry ME, McColley SA. Minorities are underrepresented in clinical trials of pharmaceutical agents for cystic fibrosis. Ann Am Thorac Soc. 2016;13(10):1721–5.
17. Foundation CF. CF Foundation seeks input from communities of color. In: Foundation CF, (ed.). November 18, 2020. https://www.cff.org/news/2020-11/cf-foundation-seeks-input-communities color#:~:text=Hearing%20from%20diverse%20voices%20is,action %20against%20racism%20and%20discrimination.
18. McGarry ME, Neuhaus JM, Nielson DW, Burchard E, Ly NP. Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: a longitudinal analysis. Pediatr Pulmonol. 2017;52(12):1550–7.
19. Paradies Y, Ben J, Denson N, Elias A, Priest N, Pieterse A, et al. Racism as a determinant of health: a systematic review and meta-analysis. PLoS One. 2015;10(9):e0138511.
20. Georgiopoulos AM, Christon LM, Filigino SS, Mueller A, Prieur MG, Boat TF, et al. Promoting emotional wellness in children with CF, part II: mental health assessment and intervention. Pediatr Pulmonol. 2021;56 (Suppl 1):S107–S22.
21. Roberts AL, Gilman SE, Breslau J, Breslau N, Koenen KC. Race/ethnic differences in exposure to traumatic events, development of post-traumatic stress disorder, and treatment-seeking for post-traumatic stress disorder in the United States. Psychol Med. 2011;41(1):71–83.
22. Kim GM, Lim JY, Kim EJ, Park SM. Resilience of patients with chronic diseases: a systematic review. Health Soc Care Community. 2019;27(4):797–807.
23. Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004;53(RR-13):1–36.
24. Health GDoP. History of the newborn screening program. 2019.
25. Bosch B, Bilton D, Sosnay P, Ranaig KS, Mak DYF, Ishiguro H, et al. Ethnicity impacts the cystic fibrosis diagnosis: a note of caution. J Cyst Fibros. 2017;16(4):488–91.
26. Pique L, Graham S, Pearl M, Kharrazi M, Schrijver I. Newborn screening for cystic fibrosis: implications of the CFTR variant spectrum in nonwhite patients. Genet Med. 2017;19(1):36–44.
27. Currier RJ, Sciortino S, Liu R, Bishop T, Alikhani Koupaei R, Feuchtbaum L. Genomic sequencing in cystic fibrosis newborn screening: implications of the CFTR variant spectrum in nonwhite patients. Genet Med. 2017;19(1):36–44.
28. Quon BS, Bentham WD, Unutzer J, Chan YF, Goss CH, Aitken DJ, Wagener JS. Impact of socioeconomic status, race, and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol. 2021;56(6):1496–503.
29. Pique L, Graham S, Pearl M, Kharrazi M, Schrijver I. Newborn screening for cystic fibrosis: implications of the CFTR variant spectrum in nonwhite patients. Genet Med. 2017;19(1):36–44.
30. Quon BS, Bentham WD, Unutzer J, Chan YF, Goss CH, Aitken DJ, Wagener JS. Impact of socioeconomic status, race, and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol. 2021;56(6):1496–503.